Familial adenomatous polyposis (FAP) is often due to adenomatous polyposis coli (APC) gene germline mutations. Somatic APC defects are found in about 80% of colorectal cancers (CRCs) and adenomas. Rapamycin inhibits mammalian target of rapamycin (mTOR) protein, which is often expressed in human adenomas and CRCs. We sought to assess the effects of rapamycin in a mouse polyposis model in which both Apc alleles were conditionally inactivated in colon epithelium. Two days after inactivating Apc, mice were given rapamycin or vehicle in cycles of two weeks on and two weeks off. Polyps were scored endoscopically. Mice were euthanized at time points or when moribund, and tissue analyses were performed. In other studies, mice with demonstrable Apc-defective colon polyps were given rapamycin, followed by analysis of their colon tissues. The median survival of mice receiving rapamycin treatment cycles was 21.5 versus 6.5 weeks in control mice (p = 0.03), and rapamycin-treated mice had a significantly lower percentage of their colon covered with polyps (4.3+/？ 2 vs 56.5+/？ 10.8 percent, p = 0.001). Mice with Apc-deficient colon tissues that developed high grade dysplasia treated with rapamycin underwent treatment for significantly longer than mice treated with vehicle (15.8 vs 5.1 weeks, p = 0.003). In Apc-defective colon tissues, rapamycin treatment was linked to decreased levels of β-catenin and Sox9 at 7 weeks. Other effects of rapamycin in Apc-defectivecolon tissues included decreased proliferation and increased numbers of differentiated goblet cells at 7 weeks. Rapamycin did not affect β-catenin-regulated gene expression in cultured intestinal epithelial cells. Rapamycin has potent inhibitory effects in a mouse colon polyposis model, and mTOR inhibition is linked to decreased proliferation and increased expression of differentiation markers in Apc-mutant colon epithelium and delays development of dysplasia. Our findings highlight the possibility that mTOR inhibitors may have relevance for polyposis inhibition approaches in FAP patients.
References
[1]
Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, et al. (2013) The way Wnt works: components and mechanism. Growth Factors 31: 1–31.
[2]
Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM (2008) Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A 105: 13544–13549.
[3]
Tuech JJ, Pessaux P, Regenet N, Ziani M, Ollier JC, et al. (2004) Endoscopic transanal resection using the urological resectoscope in the management of patients with rectal villous adenomas. Int J Colorectal Dis 19: 569–573.
[4]
Nozawa H, Watanabe T, Nagawa H (2007) Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 251: 105–113.
[5]
Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25: 6436–6446.
[6]
Alayev A, Holz MK (2013) mTOR signaling for biological control and cancer. J Cell Physiol.
[7]
Roig AI, Eskiocak U, Hight SK, Kim SB, Delgado O, et al. (2010) Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology 138: 1012–1021 e1011–1015.
[8]
Piso P, Dahlke MH, Mirena P, Schmidt U, Aselmann H, et al. (2004) Total mesorectal excision for middle and lower rectal cancer: a single institution experience with 337 consecutive patients. J Surg Oncol 86: 115–121.
[9]
Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, et al. (2009) Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 10: 44–52.
[10]
Knaus J (1999) Functional results of total mesorectal excision for rectal cancer. Int J Surg Investig 1: 263–267.
[11]
Staal FJ, Noort Mv M, Strous GJ, Clevers HC (2002) Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 3: 63–68.
[12]
Hildebrandt W, Hamann A, Krakowski-Roosen H, Kinscherf R, Dugi K, et al. (2004) Effect of thiol antioxidant on body fat and insulin reactivity. J Mol Med (Berl) 82: 336–344.
[13]
Ponnurangam S, Standing D, Rangarajan P, Subramaniam D (2013) Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth. Mol Cancer Ther.
[14]
Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, et al. (2010) Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Oncogene 29: 1553–1560.
[15]
Miller SJ, Heist KA, Feng Y, Galban CJ, Rehemtulla A, et al. (2012) Multimodal imaging of growth and rapamycin-induced regression of colonic adenomas in apc mutation-dependent mouse. Transl Oncol 5: 313–320.
[16]
Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, et al. (2007) Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67: 9721–9730.
[17]
Rodel F, Schaller U, Schultze-Mosgau S, Beuscher HU, Keilholz L, et al. (2004) The induction of TGF-beta(1) and NF-kappaB parallels a biphasic time course of leukocyte/endothelial cell adhesion following low-dose X-irradiation. Strahlenther Onkol 180: 194–200.
[18]
Kenniston JA, Burton RE, Siddiqui SM, Baker TA, Sauer RT (2004) Effects of local protein stability and the geometric position of the substrate degradation tag on the efficiency of ClpXP denaturation and degradation. J Struct Biol 146: 130–140.
